1.	Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AHCC06, NCT01135056
2.	SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P101103, NCT01482442
3.	Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: P100701, NCT01383746
4.	Pasireotide, Everolimus and Selective Internal Radioemboilization Therapy for Unresectable Hepatic Metastases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI2031-11, NCT01469572
5.	Phase II Study of Chemotherapy and Selective Internal Radiation Therapy Comprising Yttrium Y 90 Resin Microspheres in Patients With Colorectal Cancer Metastatic to the Liver Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CCCGHS-CHEMO-SIRT, NCT00408551
6.	Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: RAD050, 2008-005609-21, NCT01186263
7.	Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: TRYPHON, NCT01686880
8.	Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib Phase: Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0552, NCT01432119